About Race Oncology Ltd Company

Race Oncology Ltd is an clinical stage biopharmaceutical company focusing on cancer treatment. Its asset bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult & paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. Race's reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where it could deliver cardioprotection and enhanced anti-cancer activity in solid tumours. The company is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.